Literature DB >> 12193207

Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL.

Ming Zhao1, Yawei Liu, Xiaofei Wang, Liguo New, Jiahuai Han, Ulf T Brunk.   

Abstract

Endocytosis of oxidized low density lipoproteins (oxLDL) by macrophages, mediated by scavenger receptors, is thought to play a central role in foam cell formation and, thus, in the pathogenesis of atherosclerosis. OxLDL activates several MAP kinases, including the ERK, JNK and p38 MAP kinases, but the role of these activations in oxLDL uptake has not been studied. In the present investigation, we find that SB203580, a specific inhibitor of p38, blocks oxLDL-exposed J774 cells from becoming foam cells. Inhibition of foam cell formation by blockade of the p38 pathway is, at least in part, due to inhibition of oxLDL-induced up-regulation of the scavenger receptor CD36. Using pharmaceutical inhibitors and dominant active MAP kinase kinases, we demonstrated that activation of the p38 pathway, but not the ERK or JNK pathways, is necessary and sufficient to transactivate PPARgamma, a nuclear receptor that has recently been shown to play a pivotal role in oxLDL-induced CD36 expression. Our results for the first time demonstrate a regulation of CD36 by p38, and the importance of the p38 pathway in regulation of foam cell formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193207     DOI: 10.1034/j.1600-0463.2002.100604.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  28 in total

Review 1.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

2.  Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells.

Authors:  Hesham M El-Shewy; Mimi Sohn; Parker Wilson; Mi Hye Lee; Samar M Hammad; Louis M Luttrell; Ayad A Jaffa
Journal:  Mol Endocrinol       Date:  2012-03-15

3.  Challenges in Drug Discovery for Thiazolidinedione Substitute.

Authors:  Jianping Ye
Journal:  Yao Xue Xue Bao       Date:  2011-10-01

Review 4.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

5.  Effects of andrographolide on the activation of mitogen activated protein kinases and nuclear factor-κB in mouse peritoneal macrophage-derived foam cells.

Authors:  Fu-xing Li; Shu-sheng Li
Journal:  Chin J Integr Med       Date:  2011-04-26       Impact factor: 1.978

6.  Kimchi methanol extract and the kimchi active compound, 3'-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, downregulate CD36 in THP-1 macrophages stimulated by oxLDL.

Authors:  Ye-Rang Yun; Hyun-Ju Kim; Yeong-Ok Song
Journal:  J Med Food       Date:  2014-07-10       Impact factor: 2.786

Review 7.  Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?

Authors:  Akanksha Gupta; Sonika Bhatnagar
Journal:  OMICS       Date:  2015-12

Review 8.  MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

Authors:  Anthony J Muslin
Journal:  Clin Sci (Lond)       Date:  2008-10       Impact factor: 6.124

9.  Pro-angiogenic induction of myeloid cells for therapeutic angiogenesis can induce mitogen-activated protein kinase p38-dependent foam cell formation.

Authors:  Eva Rohde; Katharina Schallmoser; Andreas Reinisch; Nicole A Hofmann; Thomas Pfeifer; Eleonore Fröhlich; Gerald Rechberger; Gerhard Lanzer; Dagmar Kratky; Dirk Strunk
Journal:  Cytotherapy       Date:  2010-12-03       Impact factor: 5.414

10.  Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation.

Authors:  Francisco J O Rios; Mariana M Koga; Matheus Ferracini; Sonia Jancar
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.